New study brings HIV prevention and treatment to the Driver's seat
NCT ID NCT07000513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to help 400 male commercial minibus drivers in Nigeria use HIV self-testing and long-acting injectable medications for both HIV treatment and prevention. Drivers will be trained as peer educators to promote these tools among their community. The goal is to make it easier for busy drivers to stay healthy without frequent clinic visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
National Institute of Medical Research
Lagos, Lagos, Nigeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
- Home care plus nutrition may cut post-hospital deaths in HIV — a trial puts it to the test
- Heavy drinking and risky sex: a text-based intervention aims to cut HIV risk
- Pharmacists on the front line: a new strategy to fight heart disease in people with HIV
- Early HIV treatment may shield immune cells from lasting damage